Goldman Sachs
BCRX icon

Goldman Sachs’s BioCryst Pharmaceuticals BCRX Stock Holding History

Goldman Sachs’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-190,600
Closed -$999K – 6343
2017
Q3 		$999K Buy
190,600
+12,600
+7% +$64.5K ﹤0.01% 4569
2017
Q2 		$990K Buy
+178,000
New +$1.08M ﹤0.01% 4466

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Goldman Sachs's BCRX Position: Q1 2026 in Review

Goldman Sachs reduced its BioCryst Pharmaceuticals (BCRX) stake by 27% in Q1 2026, selling an estimated $6.72M and leaving 2,347,443 shares worth $22.3M. The position accounts for ﹤0.01% of the portfolio, ranked #2331.

Goldman Sachs first reported a position in BCRX in Q2 2013 and has held it in 52 quarters since. The position peaked at $31.6M in Q2 2025. 301 funds tracked by Wall St. Rank hold BCRX as of Q1 2026.

  • Goldman Sachs held 2,347,443 shares of BioCryst Pharmaceuticals worth $22.3M as of Q1 2026.
  • Goldman Sachs sold 865,342 BioCryst Pharmaceuticals shares in Q1 2026, an estimated $6.72M.
  • BioCryst Pharmaceuticals made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #2331 holding.
  • Goldman Sachs first reported a position in BioCryst Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • Goldman Sachs's BioCryst Pharmaceuticals position peaked at $31.6M in Q2 2025.
  • 301 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.